ArticleFrontiers in neurology
Dynamic changes and associated factors of asymmetric prominent vessel sign in atherosclerotic anterior circulation acute ischemic stroke: a preliminary study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the dynamic changes, influencing factors, and prognostic significance of the asymmetric prominent vessel sign (APVS) in patients with atherosclerotic anterior circulation acute ischemic stroke (AIS). Methods: Patients with atherosclerotic anterior circulation AIS who were admitted within 48 h after symptom onset and had complete baseline and follow-up diffusion-weighted imaging (DWI) and susceptibility-weighted imaging (SWI) data obtained 10-14 days after treatment were retrospectively enrolled. Changes in APVS were evaluated. Clinical and imaging data were collected, including the degree of vascular stenosis, baseline SWI-DWI mismatch, NIHSS scores before and after treatment, infarct volume, SWI-Alberta Stroke Program Early CT Score (SWI-ASPECTS), early neurological deterioration (END) within 7 days, and 90-day mRS scores. According to the difference in SWI-ASPECTS scores before and after treatment, patients were categorized into the significant APVS change group (≥2 points) and the non-significant APVS change group (0-1 point). Univariate analyses were performed to preliminarily explore the factors associated with APVS changes and the relationship between APVS changes and clinical outcomes. Results: A total of 34 patients were included, among whom 11 were assigned to the significant APVS change group. After 10-14 days of standardized conservative medical treatment, the APVS extent remained unchanged in 38.2% of patients, decreased to varying degrees in 58.8% (including complete disappearance in 17.6%), and increased in only 2.9% of patients. Univariate analysis demonstrated that patients in the significant change group had larger baseline infarct volumes ( Conclusion: Following standardized treatment for 10-14 days, APVS extent decreased or even disappeared in most patients, whereas persistent APVS was observed in a subset of patients. Baseline and post-treatment infarct volumes, degree of vascular stenosis, and baseline SWI-ASPECTS scores may influence APVS evolution. However, APVS changes were not significantly associated with clinical prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.